Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Transfer Clinical Trial of UX111 for MPS IIIA
NCT02716246Phase 3Recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Apr 2016
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 3
01
Overview
A Phase 3 trial of rebisufligene etisparvovec in mucopolysaccharidosis type III, sponsored by Ultragenyx Pharmaceutical Inc.. Started Apr 2016; status: recruiting.
02
Drugs
rebisufligene etisparvovec
03
Conditions
mucopolysaccharidosis type III
Beyond the preview
Go deeper on NCT02716246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716246.